264 related articles for article (PubMed ID: 16809315)
1. Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling.
Hidmark AS; Nordström EK; Dosenovic P; Forsell MN; Liljeström P; Karlsson Hedestam GB
J Virol; 2006 Jul; 80(14):7100-10. PubMed ID: 16809315
[TBL] [Abstract][Full Text] [Related]
2. Alpha interferon is a powerful adjuvant for a recombinant protein vaccine against foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response.
Cheng G; Zhao X; Yan W; Wang W; Zuo X; Huang K; Liu Y; Chen J; Wang J; Cong W; Liu M; Gao H; Chen J; Lu Y; Zheng Z
Vaccine; 2007 Jul; 25(28):5199-208. PubMed ID: 17555848
[TBL] [Abstract][Full Text] [Related]
3. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice.
Liu WJ; Wang XJ; Clark DC; Lobigs M; Hall RA; Khromykh AA
J Virol; 2006 Mar; 80(5):2396-404. PubMed ID: 16474146
[TBL] [Abstract][Full Text] [Related]
4. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine.
Fleeton MN; Liljeström P; Sheahan BJ; Atkins GJ
J Gen Virol; 2000 Mar; 81(Pt 3):749-58. PubMed ID: 10675413
[TBL] [Abstract][Full Text] [Related]
5. Immunogenic and replicative properties of classical swine fever virus replicon particles modified to induce IFN-α/β and carry foreign genes.
Suter R; Summerfield A; Thomann-Harwood LJ; McCullough KC; Tratschin JD; Ruggli N
Vaccine; 2011 Feb; 29(7):1491-503. PubMed ID: 21184857
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge.
Fleeton MN; Sheahan BJ; Gould EA; Atkins GJ; Liljestr M P
J Gen Virol; 1999 May; 80 ( Pt 5)():1189-1198. PubMed ID: 10355766
[TBL] [Abstract][Full Text] [Related]
7. Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming.
Huckriede A; Bungener L; Holtrop M; de Vries J; Waarts BL; Daemen T; Wilschut J
Vaccine; 2004 Mar; 22(9-10):1104-13. PubMed ID: 15003637
[TBL] [Abstract][Full Text] [Related]
8. Interferon-β modulates type 1 immunity during influenza virus infection.
Yoo JK; Baker DP; Fish EN
Antiviral Res; 2010 Oct; 88(1):64-71. PubMed ID: 20659503
[TBL] [Abstract][Full Text] [Related]
9. Human MxA protein protects mice lacking a functional alpha/beta interferon system against La crosse virus and other lethal viral infections.
Hefti HP; Frese M; Landis H; Di Paolo C; Aguzzi A; Haller O; Pavlovic J
J Virol; 1999 Aug; 73(8):6984-91. PubMed ID: 10400797
[TBL] [Abstract][Full Text] [Related]
10. Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses.
Fink K; Lang KS; Manjarrez-Orduno N; Junt T; Senn BM; Holdener M; Akira S; Zinkernagel RM; Hengartner H
Eur J Immunol; 2006 Aug; 36(8):2094-105. PubMed ID: 16810635
[TBL] [Abstract][Full Text] [Related]
11. Distinctive TLR7 signaling, type I IFN production, and attenuated innate and adaptive immune responses to yellow fever virus in a primate reservoir host.
Mandl JN; Akondy R; Lawson B; Kozyr N; Staprans SI; Ahmed R; Feinberg MB
J Immunol; 2011 Jun; 186(11):6406-16. PubMed ID: 21515797
[TBL] [Abstract][Full Text] [Related]
12. TLR2 and TLR4 signaling shapes specific antibody responses to Salmonella typhi antigens.
Cervantes-Barragán L; Gil-Cruz C; Pastelin-Palacios R; Lang KS; Isibasi A; Ludewig B; López-Macías C
Eur J Immunol; 2009 Jan; 39(1):126-35. PubMed ID: 19130558
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity.
Takeshita F; Tanaka T; Matsuda T; Tozuka M; Kobiyama K; Saha S; Matsui K; Ishii KJ; Coban C; Akira S; Ishii N; Suzuki K; Klinman DM; Okuda K; Sasaki S
J Virol; 2006 Jul; 80(13):6218-24. PubMed ID: 16775309
[TBL] [Abstract][Full Text] [Related]
14. The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines.
Thompson JM; Whitmore AC; Staats HF; Johnston R
Vaccine; 2008 Sep; 26(39):4998-5003. PubMed ID: 18656518
[TBL] [Abstract][Full Text] [Related]
15. The adjuvant activity of alphavirus replicons is enhanced by incorporating the microbial molecule flagellin into the replicon.
Knudsen ML; Johansson DX; Kostic L; Nordström EK; Tegerstedt K; Pasetto A; Applequist SE; Ljungberg K; Sirard JC; Liljeström P
PLoS One; 2013; 8(6):e65964. PubMed ID: 23785460
[TBL] [Abstract][Full Text] [Related]
16. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.
Pushko P; Geisbert J; Parker M; Jahrling P; Smith J
J Virol; 2001 Dec; 75(23):11677-85. PubMed ID: 11689649
[TBL] [Abstract][Full Text] [Related]
17. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.
Martinez-Sobrido L; Gitiban N; Fernandez-Sesma A; Cros J; Mertz SE; Jewell NA; Hammond S; Flano E; Durbin RK; García-Sastre A; Durbin JE
J Virol; 2006 Feb; 80(3):1130-9. PubMed ID: 16414990
[TBL] [Abstract][Full Text] [Related]
18. MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells.
Chen M; Barnfield C; Näslund TI; Fleeton MN; Liljeström P
J Virol; 2005 Mar; 79(5):2964-72. PubMed ID: 15709016
[TBL] [Abstract][Full Text] [Related]
19. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses.
Heer AK; Shamshiev A; Donda A; Uematsu S; Akira S; Kopf M; Marsland BJ
J Immunol; 2007 Feb; 178(4):2182-91. PubMed ID: 17277123
[TBL] [Abstract][Full Text] [Related]
20. Immunoprotective activity of a Salmonid Alphavirus Vaccine: comparison of the immune responses induced by inactivated whole virus antigen formulations based on CpG class B oligonucleotides and poly I:C alone or combined with an oil adjuvant.
Thim HL; Iliev DB; Christie KE; Villoing S; McLoughlin MF; Strandskog G; Jørgensen JB
Vaccine; 2012 Jul; 30(32):4828-34. PubMed ID: 22634299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
